Rexahn Pharmaceuticals Issued Japanese Patent For Anti-cancer Compound Archexin(R)

Main Category: Cancer / Oncology
Also Included In: Clinical Trials / Drug Trials
Article Date: 09 Mar 2010 - 23:00 PDT

email to a friend   printer friendly   opinions  

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued a patent for its novel anti-cancer compound, Archexin®.

"The Japanese patent award is another step forward in the development of one of our lead clinical drug candidates, Archexin," said Dr. Chang Ahn, Rexahn's Chairman and Chief Executive Officer. "In addition to strengthening our intellectual property portfolio, we are pleased with the progress of Archexin's ongoing Phase II clinical trial for the treatment of pancreatic cancer. Patient enrollment continues at multiple sites in the US and abroad and we expect to have preliminary results in the fourth quarter of 2010."

Archexin is a first in class, potent inhibitor of Akt protein kinase in the treatment of cancer. Akt regulates signal processes of cell proliferation and survival, angiogenesis, and drug resistance in cancer. Archexin is being developed to treat solid tumors and has FDA Orphan drug designation for RCC, pancreatic, stomach, glioblastoma, and ovarian cancers. Archexin is in Phase II clinical development for pancreatic cancer as lead indication.

Source
Rexahn Pharmaceuticals, Inc.

• Additional
• References
• Citations